IMPLANTABLE DEVICE FOR THE DELIVERY OF OCTREOTIDE AND METHODS OF USE THEREOF
This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active octreotide at a constant rate for an extended period of time and methods of manufactures thereof. The device is very bio-compatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of octreotide to tissues or organs.
1 .- 11 . (canceled)
12 . A method of delivering octreotide or a pharmaceutically acceptable salt thereof to a subject, comprising implanting an implantable device into the subject, in which the implantable device comprises a polyurethane-based polymer configured to provide a cylindrically shaped reservoir, wherein the reservoir is sealed after being charged with an effective amount of a solid formulation comprising octreotide or a pharmaceutically acceptable salt thereof, such that the release of the octreotide or a pharmaceutically acceptable salt thereof at a substantially zero order rate in vitro by diffusion through the polyurethane-based polymer generally increases with the selection of polyurethane-based polymers of increasing percent equilibrium water content (% EWC).
13 . The method of claim 12 in which the % EWC of the polyurethane-based polymer ranges up to 150% of the weight of dry polyurethane resin.
14 . The method of claim 12 in which the % EWC of the polyurethane-based polymer ranges from about 8% to about 30%.
15 . The method of claim 12 in which the % EWC of the polyurethane-based polymer ranges from about 9% to about 24%.
16 . The method of claim 12 in which the solid formulation comprises octreotide acetate.
17 . The method of claim 16 in which the solid formulation further comprises stearic acid (SA), hydroxypropylcellulose (HPC), or a combination thereof.
18 . The method of claim 12 in which octreotide or a pharmaceutically acceptable salt thereof is released at a rate ranging from about 10 to about 2000 μg/day/cm 2 .
19 . An implantable drug deliver device for releasing octreotide or a pharmaceutically acceptable salt thereof at a substantially zero order rate in vitro by diffusion through a polyurethane-based polymer for an extended period of time, said implantable drug delivery device comprising a polyurethane-based polymer configured to provide a cylindrically shaped reservoir, wherein the reservoir is sealed after being charged with an effective amount of a solid formulation comprising octreotide or a pharmaceutically acceptable salt thereof and the polyurethane-based polymer exhibits a percent equilibrium water content (% EWC) of up to 150% by weight of dry polyurethane resin.
20 . The implantable drug delivery device of claim 19 in which the polyurethane-based polymer exhibits a % EWC of about 30% or less.
21 . The implantable drug delivery device of claim 20 in which the polyurethane-based polymer exhibits a % EWC ranging from about 8% to about 30%.
22 . The implantable drug delivery device of claim 20 in which the polyurethane-based polymer exhibits a % EWC ranging from about 9% to about 24%.
23 . The implantable drug delivery device of claim 19 in which the solid formulation includes one or more pharmaceutically acceptable carriers that are not required for the substantially zero order release rate in vitro of the octreotide or a pharmaceutically acceptable salt thereof through the polyurethane-based polymer.
24 . The implantable drug delivery device of claim 23 in which the one or more pharmaceutically acceptable carriers are not required for the substantially zero order release rate in vitro of the octreotide or a pharmaceutically acceptable salt thereof as governed by Fick's Law of Diffusion.
25 . The implantable drug delivery device of claim 19 in which the solid formulation comprises octreotide acetate.
26 . The implantable drug delivery device of claim 25 in which the solid formulation further comprises stearic acid (SA), hydroxypropylcellulose (HPC), or a combination thereof.
27 . The implantable drug delivery device of claim 19 in which octreotide or a pharmaceutically acceptable salt thereof is released at a rate ranging from about 10 to about 2000 μg/day/cm 2 .